Market Cap
$2.3M
TCRT
Alaunos Therapeutics, Inc.
$0.9100 ▼ -1.09%
Prev close $0.9200Market cap$2.3M
High Impact Filing (8/10)3 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on TCRT right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
17 funds
Inst. Value
$200.0K
Inst. Activity
3 buys / 1 sells
SEC Reports
3
Press Releases
1
Price chart 30d -45.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 offering
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants
Aug 6, 2026 Insider
Weis Holger was granted 4,363 shares
CEO @ $2.01 ($8.8K)
Jul 23, 2026 Insider
Vieser Jaime was granted 8,789 shares
Director @ $1.92 ($16.9K)
Jul 23, 2026 Insider
Jul 3, 2026 SEC Weis Holger was granted 4,568 shares
CEO @ $1.92 ($8.8K)
Alaunos Therapeutics announced new preclinical statistical analysis for ALN1003, showing lower liver weight after adjust
8-K — Impact 3/10
Jun 30, 2026 Inst.
UBS Group AG — TRIM
992 shares ($2.2K)
Jun 30, 2026 Inst.
May 26, 2026 SEC MORGAN STANLEY — ADD
836 shares ($1.9K)
Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, its oral non-hormonal obesity candidate, sh
8-K — Impact 6/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Dec 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% |
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 1 neutral · avg impact 5.7/10.Plus 1 press releases.
NEUTRAL8-K3/10
Alaunos Therapeutics announced new preclinical statistical analysis for ALN1003, showing lower liver
Jul 3, 2026
BEARISH8-K6/10
Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, its oral non-hormonal o
May 26, 2026
BEARISH8-K8/10
Alaunos Therapeutics (TCRT) received a delisting notice from Nasdaq due to failing to maintain the $
Apr 15, 2026
MIXED6/10
Alaunos Therapeutics released early non-GLP preclinical data from two diet-induced obesity (DIO) mou
Mar 2, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
Clinical Trial
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
Phase Phase 2 — TERMINATED
Sep 30, 2026
Clinical Trial
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
Phase Phase 3 — TERMINATED
Sep 30, 2026
Clinical Trial
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
Phase Phase 2 — TERMINATED
Sep 30, 2026
Clinical Trial
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
Phase Phase 3 — TERMINATED
Sep 30, 2026
Clinical Trial
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Phase Phase 2 — TERMINATED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own TCRT (from quarterly 13F filings) and who is adding or trimming.
17 institutional holders with $200.0K total value (88,419 shares) as of 2026-Q2. Top holders: BlackRock,, GEODE, VANGUARD. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 21,353 | $48.3K | 24.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 19,356 | $43.8K | 21.9% | — |
| VANGUARD FIDUCIARY TRUST CO | 15,497 | $35.0K | 17.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 14,063 | $31.8K | 15.9% | — |
| CITADEL ADVISORS LLC | 11,870 | $26.8K | 13.4% | — |
| OSAIC HOLDINGS, INC. | 1,731 | $3.9K | 2.0% | ADD +65.3% |
| Arax Advisory Partners | 1,216 | $2.7K | 1.4% | — |
| UBS Group AG | 992 | $2.2K | 1.1% | TRIM -56.4% |
| MORGAN STANLEY | 836 | $1.9K | 0.9% | ADD +28.0% |
| Vanguard Global Advisers, LLC | 501 | $1.1K | 0.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | TRIM | 2,274 | 992 | -56.4% | $2.2K |
| MORGAN STANLEY | ADD | 653 | 836 | +28.0% | $1.9K |
| ROYAL BANK OF CANADA | DOUBLED | 185 | 375 | +102.7% | $1.0K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 190 | 388 | +104.2% | $877.00 |
| UBS Group AG | ADD | 1,309 | 2,274 | +73.7% | $6.5K |
| OSAIC HOLDINGS, INC. | ADD | 1,076 | 1,779 | +65.3% | $5.1K |
| MORGAN STANLEY | TRIM | 1,647 | 653 | -60.4% | $1.9K |
| VANGUARD GROUP INC | ADD | 20,972 | 30,061 | +43.3% | $97.1K |
| UBS Group AG | NEAR_EXIT | 6,815 | 1,533 | -77.5% | $3.7K |
| OSAIC HOLDINGS, INC. | ADD | 890 | 1,165 | +30.9% | $2.8K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 11 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Weis Holger | CEO | AWARD | 4,363 | $2.01 | $8.8K |
| Jul 23, 2026 | Vieser Jaime | Director | AWARD | 8,789 | $1.92 | $16.9K |
| Jul 23, 2026 | Weis Holger | CEO | AWARD | 4,568 | $1.92 | $8.8K |
| Jul 23, 2026 | Jerman Michael Allen | Director | AWARD | 8,138 | $1.92 | $15.6K |
| Jul 23, 2026 | Postma Robert W | Director | AWARD | 8,463 | $1.92 | $16.2K |
| Jun 30, 2026 | Weis Holger | Chief Executive Officer | AWARD | 3,880 | $2.26 | $8.8K |
| Jun 12, 2026 | Weis Holger | Chief Executive Officer | AWARD | 7,761 | $2.26 | $17.5K |
| May 22, 2026 | Weis Holger | Chief Executive Officer | AWARD | 3,700 | $2.37 | $8.8K |
| Apr 29, 2026 | Jerman Michael Allen | Director | AWARD | 6,032 | $2.59 | $15.6K |
| Apr 29, 2026 | Postma Robert W | Director | AWARD | 6,274 | $2.59 | $16.2K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TCRT.
Shares short
6,075
Settlement Sep 15, 2026
Change vs prior
+6.5%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.2%
Estimate — not % of float
All TCRT filing & press-release reports (4)
- 8-K reportJul 3, 2026
- 8-K reportMay 26, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 2, 2026